- Home
- SVII vs NKTX Comparison
SVII vs NKTX Comparison
Compare SVII & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- NKTX
- Stock Information
- Founded
- SVII 2021
- NKTX 2015
- Country
- SVII United States
- NKTX United States
- Employees
- SVII N/A
- NKTX N/A
- Industry
- SVII Blank Checks
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SVII Finance
- NKTX Health Care
- Exchange
- SVII Nasdaq
- NKTX Nasdaq
- Market Cap
- SVII 117.1M
- NKTX 123.5M
- IPO Year
- SVII 2022
- NKTX 2020
- Fundamental
- Price
- SVII $11.85
- NKTX $2.20
- Analyst Decision
- SVII
- NKTX Strong Buy
- Analyst Count
- SVII 0
- NKTX 6
- Target Price
- SVII N/A
- NKTX $14.40
- AVG Volume (30 Days)
- SVII 2.2K
- NKTX 543.5K
- Earning Date
- SVII 01-01-0001
- NKTX 08-12-2025
- Dividend Yield
- SVII N/A
- NKTX N/A
- EPS Growth
- SVII N/A
- NKTX N/A
- EPS
- SVII 0.25
- NKTX N/A
- Revenue
- SVII N/A
- NKTX N/A
- Revenue This Year
- SVII N/A
- NKTX N/A
- Revenue Next Year
- SVII N/A
- NKTX N/A
- P/E Ratio
- SVII $47.78
- NKTX N/A
- Revenue Growth
- SVII N/A
- NKTX N/A
- 52 Week Low
- SVII $11.06
- NKTX $1.31
- 52 Week High
- SVII $11.90
- NKTX $7.09
- Technical
- Relative Strength Index (RSI)
- SVII 58.66
- NKTX 66.42
- Support Level
- SVII $11.75
- NKTX $1.74
- Resistance Level
- SVII $11.87
- NKTX $2.25
- Average True Range (ATR)
- SVII 0.04
- NKTX 0.12
- MACD
- SVII -0.00
- NKTX 0.04
- Stochastic Oscillator
- SVII 90.00
- NKTX 90.20
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.